How Pediatric Immune Systems Empower Cancer Immunotherapy
Source: Berkeley Lights
CAR T therapy in children with leukemia was the first FDA-approved gene modified cell therapy. In this webinar, University of Pennsylvania's Dr. David M Barrett, one of the developers of this therapy, provides insights into:
- How pediatric T cells differ from adult T cells
- Challenges to getting effective T cells from cancer patients
- How to overcome immune dysfunction
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Berkeley Lights
This website uses cookies to ensure you get the best experience on our website. Learn more